<--- Back to Details
First PageDocument Content
Medicine / Glatiramer acetate / Chronic cerebrospinal venous insufficiency / Natalizumab / McDonald criteria / Experimental autoimmune encephalomyelitis / Interferon beta-1b / Myelin / Interferon beta-1a / Multiple sclerosis / Immunology / Immune system
Date: 2014-07-07 10:35:12
Medicine
Glatiramer acetate
Chronic cerebrospinal venous insufficiency
Natalizumab
McDonald criteria
Experimental autoimmune encephalomyelitis
Interferon beta-1b
Myelin
Interferon beta-1a
Multiple sclerosis
Immunology
Immune system

Microsoft Word - Timeline of Research 7_2014

Add to Reading List

Source URL: www.nationalmssociety.org

Download Document from Source Website

File Size: 57,81 KB

Share Document on Facebook

Similar Documents

Multiple sclerosis / Medicine / Immunology / Clinical medicine / Autoimmune diseases / Neurological disorders / Neurology / Management of multiple sclerosis / Glatiramer acetate / Immunosuppressants / McDonald criteria / Diagnostic criteria for MS

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

Cytokines / Interferon beta-1a / Lifeline / TTY / Glatiramer acetate

PDF Document

DocID: 1rhTx - View Document

Cytokines / Interferon beta-1a / Glatiramer acetate / Natalizumab

PDF Document

DocID: 1ptj0 - View Document

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr COPAXONE® Glatiramer acetate

DocID: 1kIzm - View Document

Autoimmune diseases / Medicine / Immunosuppressants / Neurological disorders / Treatment of multiple sclerosis / Glatiramer acetate / Natalizumab / Mitoxantrone / Fingolimod / Multiple sclerosis / Immunology / Immune system

Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators

DocID: 1fWCE - View Document